BG Medicine Q3 Revenues Spike as Restructuring Aims to Ramp up Commercialization | GenomeWeb

NEW YORK (GenomeWeb News) – BG Medicine said today that revenues in the third quarter rose 258 percent year over year on the sale of it BGM Galectin-3 test.

Separately, the Waltham, Mass.-based firm also announced a commercialization strategy intended to accelerate adoption of its cardiovascular diagnostics tests.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.